<DOC>
	<DOCNO>NCT01438489</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety MEDI-546 compare placebo subject chronic , moderately-to-severely active systemic lupus erythematosus ( SLE ) inadequate response standard care treatment SLE .</brief_summary>
	<brief_title>A Study Efficacy Safety MEDI-546 Systemic Lupus Erythematosus</brief_title>
	<detailed_description>This Phase 2 , multinational , multicenter , randomize , double-blind , placebo control , parallel-group study evaluate efficacy safety 2 intravenous ( IV ) treatment regimens adult participant chronic , moderately-to-severely active SLE inadequate response SOC SLE . The investigational product ( anifrolumab placebo ) administer fix dose every 4 week ( 28 day ) total 13 dos .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Fulfills least 4 11 American College Rheumatology ( ACR ) criteria systemic lupus erythematosus ( SLE ) include positive antinuclear antibody ( ANA ) great equal 1:80 elevate antidoublestranded DNA antiSmith antibody screen Pediatric adult SLE chronic disease activity great equal 24 week Weight great equal 40 kg Currently receive stable dose oral prednisone ( equivalent ) less equal 40 mg/day and/or antimalarials/immunosuppressives Active moderate severe SLE disease base SLE disease activity score ( SLEDAI ) British Isles Lupus Assessment Group Index ( BILAG ) Physicians Global Assessment No evidence cervical malignancy Pap smear within 2 year randomization Female participant must willing avoid pregnancy Negative tuberculosis ( TB ) test newly positive TB test due latent TB treatment must initiate randomization . Active severe SLEdriven renal disease unstable renal disease prior screen Active severe unstable neuropsychiatric SLE Clinically significant active infection include ongoing chronic infection History human immunodeficiency virus ( HIV ) Confirmed Positive test hepatitis B positive test hepatitis C History severe herpes infection herpes encephalitis , ophthalmic herpes , disseminate herpes Live attenuate vaccine within 4 week prior screen Participants significant hematologic abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MEDI-546</keyword>
	<keyword>Anifrolumab</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
</DOC>